dr. rizvi on activity and toxicity of pembrolizumab for nsclc
Published 10 years ago • 252 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:03
dr. rizvi discusses pembrolizumab for non-small cell lung cancer
-
0:56
dr. rizvi on the utility of trastuzumab deruxtecan in nsclc
-
1:29
dr. rizvi on utilizing molecular characteristics to inform treatment decisions in nsclc
-
1:16
dr. rizvi on pd-1 and pd-l1 inhibitors in lung cancer
-
1:15
dr. rizvi on pd-1 and pd-l1 inhibitors in lung cancer
-
5:43
duration of upfront immunotherapy for nsclc - o
-
0:51
dr. rizvi on pd-l1 as a biomarker for immunotherapy agents in lung cancer
-
1:15
dr. rizvi on nivolumab plus erlotinib in patients with egfr mt nsclc
-
2:15
dr. ramalingam on pembrolizumab and chemotherapy in nsclc
-
48:15
immunotherapy for lung cancer: pd-1 and beyond, with naiyer rizvi
-
1:00
dr. rizvi on pseudoprogression in lung cancer after immunotherapy
-
1:39
pembrolizumab and epacadostat for nsclc: echo-306/keynote-715
-
0:53
dr. sequist on pembrolizumab monotherapy in nonsquamous nsclc
-
0:36
dr. camidge on the fda approval of pembrolizumab for squamous nsclc
-
17:30
immunotherapy in lung cancer: panacea vs. reality?
-
1:36
dr. hurvitz on pembrolizumab for tnbc
-
1:02
dr. danae delivanis pembrolizumab and nivolumab in metastatic melanoma
-
1:00
dr. papadimitrakopoulou provides an update on pembrolizumab for lung cancer
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc